Carl Icahn takes stake in Bristol Myers
- Author: Ronnie Bowen Feb 23, 2017,
Feb 23, 2017, 0:49
Bristol-Myers Squibb Company (NYSE:BMY) reported its last quarter results on 01/26/2017. The stock price recently experienced a 5-day gain of 5.29% with 1.5 average true range (ATR). BlackRock Institutional Trust Company N.A. raised its position in shares of Bristol-Myers Squibb Company by 5.7% in the third quarter. The stock volatility for week was 2.36% while for month was 2.92%.The stock, as of last close, traded 18.65% to its 52 week low and was changed -28.25% from its 52 week high.
While trading at volume below than average, Apple Inc. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was 0 percent. Finally, Mascoma Wealth Management LLC purchased a new position in shares of Bristol-Myers Squibb Company during the fourth quarter worth about $145,000. During its last trading session, Stock traded with the total exchanged volume of 9.33 million shares. For the next 5 years, Bristol-Myers Squibb Company is expecting Growth of 14.33% per annum, whereas in the past 5 years the growth was 5.73% per annum.
Bristol-Myers Squibb shares spiked as much as 4% in afternoon trading on a Dow Jones report that Carl Icahn has purchased a stake in the pharma giant. Institutional investors and hedge funds own 69.67% of the company's stock. Finally, J P Morgan Chase & Co restated a buy rating on shares of Bristol-Myers Squibb Company in a research note on Saturday, January 21st. The company's revenue for the quarter was up 22.3% on a year-over-year basis. The analyst projections are $0.75 in EPS on $4.74 billion in revenues. The stock's 50-day moving average is $53.60 and its 200 day moving average is $55.66. Bristol-Myers Squibb Company P/E (price to earnings) ratio is 20.54 and Forward P/E ratio of 17.68. The biopharmaceutical company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.67 by $0.04. The company's net profit margin has achieved the current level of 22.9 percent and possesses 74.6 percent gross margin.
01/20/2017 - Bristol-Myers Squibb Company was downgraded to "market perform" by analysts at Cowen.
Now, a Supermarket Chain Faces a Boycott for Selling Trump Wine
While the retailer said the decision came down to sales performance, the company faced backlash from President Trump on Twitter. In contrast, sales of Trump wine more than doubled from 2015 to 2016, according to Virginia ABC spokesperson Valerie Hubbard.
The business also recently announced a quarterly dividend, which was paid on Wednesday, February 1st. Investors of record on Friday, January 6th were issued a dividend of $0.39 per share.
01/27/2017 - Bristol-Myers Squibb Company had its "buy" rating reiterated by analysts at Jefferies. The ex-dividend date was Wednesday, January 4th. Bristol-Myers Squibb Company's dividend payout ratio (DPR) is now 58.87%.
Several other large investors have also bought and sold shares of BMY. BMO Capital Markets now has a $45.00 target price on the biopharmaceutical company's stock.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017? One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and ten have issued a buy rating to the stock.